Evidence map›Paper›PMID 34896314›Full record

ArticleInternational journal for parasitology2022

B cell clonal expansion and mutation in the immunoglobulin heavy chain variable domain in response to Pfs230 and Pfs25 malaria vaccines.

Camila H Coelho, Jacob D Galson, Johannes Trück, Patrick E Duffy

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal for parasitology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Camila H CoelhoLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Jacob D GalsonDivision of Immunology, University Children's Hospital Zurich and Clinical Research Center, University of Zurich, Switzerland; Alchemab Therapeutics Ltd, London, United Kingdom.
Johannes TrückDivision of Immunology, University Children's Hospital Zurich and Clinical Research Center, University of Zurich, Switzerland.
Patrick E DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA. Electronic address: patrick.duffy@nih.gov.
National Institute of Allergy and Infectious Diseases · USUniversity of Zurich · CH

Funding

Vaccines to Interrupt Malaria Transmission: Clinical DevelopmentZIAAI001009 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2009 to 2025
$84.8M
Mali International Center for Excellence in Research: Malaria Clinical ResearchZIAAI001056 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2009 to 2024
$43.1M
Malaria Vaccine: Pfs230-rEPAZIAAI001010 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2009 to 2015
$9.9M
Intramural NIH HHS ZIA AI001009Intramural NIH HHS ZIA AI001010Intramural NIH HHS ZIA AI001056
6 · The paper itself

Abstract

Malaria transmission-blocking vaccines induce antibodies that target Plasmodium in the mosquito vector. We recently reported that Pfs230 vaccine achieves activity superior to Pfs25 in humans. Here, we describe clonal expansion in the variable region of immunoglobulin heavy chains (VH) of antigen-specific single B cells collected from humans immunised with Pfs230D1-EPA or Pfs25-EPA conjugate vaccines formulated in Alhydrogel®. Based on studies of CD27+ memory B cells following Pfs230 vaccination, clonal expansion and somatic hypermutation was seen in four of five subjects. Pfs25 did not induce sufficient CD27+ cells for sorting; based instead on CD19+ Pfs25-reactive B cells, clonal expansion was only seen in two of five subjects. Clonal expansions and mutations in Pfs230-specific single B cells combined with the enhanced activity of Pfs230 antibodies by complement, might justify the outstanding activity of Pfs230D1 as a TBV candidate.

Indexed as

Immunoglobulin Heavy ChainsMalaria, FalciparumMalaria VaccinesAntibodies, ProtozoanAntigens, ProtozoanHumansMutationPlasmodium falciparumProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin Heavy ChainsMalaria VaccinesProtozoan ProteinsB cell sequencingClonal expansionMalaria transmission-blocking vaccinesPfs230Pfs25VH mutation

Identifiers

PMID34896314
PMCPMC9177897
OpenAlexW4200094248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.